Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up - BioCentury This Week

Om avsnittet

The importance of FDA’s approval of Bristol Myers' LAG3 inhibitor Opdualag nivolumab/relatlimab for melanoma, the pharma’s disruptive marketing strategy and what’s next among checkpoints in the clinic headline the latest BioCentury This Week podcast. BioCentury's editors also discuss why there’s still a lot of excitement regarding the IL-2 cancer pipeline despite last week’s setback for Nektar Therapeutics and the paths less traveled to raising money as the downturn grinds on. This week’s podcast is sponsored by life sciences investment firm Jeito Capital.

Reach us by sending a text

Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up

Om avsnittet

Fler avsnitt

Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways

Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs

Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Ep. 384 - Back to School Special: The global FIH trials race

Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA